Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
74.1%
-
Total 13F principal
-
$537,457,499
-
Principal change
-
+$4,492,689
-
Total reported market value
-
$417,146,853
-
Number of holders
-
36
-
Value change
-
+$6,942,248
-
Number of buys
-
16
-
Number of sells
-
17
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q1 2023
As of 31 Mar 2023,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
36 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$537,457,499
in principal (par value) of the bond.
The largest 10 bondholders included
ARISTEIA CAPITAL LLC, BRAIDWELL LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, MACKAY SHIELDS LLC, WELLS FARGO & COMPANY/MN, ORBIMED ADVISORS LLC, D. E. Shaw & Co., Inc., STATE STREET CORP, and Calamos Advisors LLC.
This page lists
36
institutional bondholders reporting positions
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.